Featured Research

from universities, journals, and other organizations

Biopharmaceutical Infrastructure Key To Lower Drug Development Costs

Date:
October 29, 2007
Source:
National Institute of Standards and Technology (NIST)
Summary:
Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annually, according to a new economic study sponsored by NIST.

A new NIST-sponsored study found that the biopharmaceutical industry spend a total of $1,219 million on infrastructure technology?884 million on the R&D technology infrastructure including bioimaging, biomarkers, informatics, and gene expression and $335 million on infrastructure for commercial manufacturing and postmarket surveillance.
Credit: NIST

Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annually, according to a new economic study* sponsored by the National Institute of Standards and Technology (NIST).

Prepared by RTI International for NIST, the study‘―s authors found that over the last two decades emphasis in new drug development has shifted from small-molecule chemicals to large-molecule proteins and other biopharmaceuticals such as human insulin, gene therapies and specialized antibiotic treatments. The report notes that the biopharmaceutical industry currently spends about $21 billion annually on research and development and has commercialized over 400 products.

Producing and maintaining the infrastructure that supports R&D, manufacturing and postmarket surveillance, including core data, methods, and standards used to determine the quality and efficacy of biopharmaceuticals, costs the industry a total of $1.2 billion annually, according to the report. The study focused on expenditures for four major categories of technical infrastructure: bioimaging, biomarkers, bioinformatics, and gene expression, as well as expenditures for infrastructure supporting processing and quality control for commercial manufacturing and activities involved with postmarket surveilliance. (See chart.)

According to the study, improvements to this infrastructure, such as better standardization of data collection and analysis, would be expected to save between 25 and 48 percent of R&D expenses for each new biopharmaceutical drug approved by the Food and Drug Administration. Better technical infrastructure is also projected to reduce the average development time per approved drug from 122 months to 98 months, a reduction of 20 percent. The study further estimated that total industry manufacturing costs could be reduced over the four major phases of manufacturing by $1.5 billion or 23 percent.

Data for the study were gathered from individual researchers and organizations including a survey of 44 technical experts whose companies represent 42 percent of the combined annual R&D spending and 49 percent of the combined annual R&D sales in biopharmaceuticals.

The ultimate beneficiaries of an improved biopharmaceutical infrastructure, wrote the study‘―s authors, "are patients who gain access to a broader array of novel therapies where development is supported by an effective technology infrastructure."

The full report, Economic Analysis of the Technology Infrastructure Needs of the U.S. Biopharmaceutical Industry, is available at: http://www.nist.gov/director/prog-ofc/report07-1.pdf.

* RTI International, Economic Analysis of the Technology Infrastructure Needs of the U.S. Biopharmaceutical Industry: Planning Report 07-01, August 2007, 201 pp.


Story Source:

The above story is based on materials provided by National Institute of Standards and Technology (NIST). Note: Materials may be edited for content and length.


Cite This Page:

National Institute of Standards and Technology (NIST). "Biopharmaceutical Infrastructure Key To Lower Drug Development Costs." ScienceDaily. ScienceDaily, 29 October 2007. <www.sciencedaily.com/releases/2007/10/071011164809.htm>.
National Institute of Standards and Technology (NIST). (2007, October 29). Biopharmaceutical Infrastructure Key To Lower Drug Development Costs. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2007/10/071011164809.htm
National Institute of Standards and Technology (NIST). "Biopharmaceutical Infrastructure Key To Lower Drug Development Costs." ScienceDaily. www.sciencedaily.com/releases/2007/10/071011164809.htm (accessed August 23, 2014).

Share This




More Matter & Energy News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Is It a Plane? No, It's a Hoverbike

Is It a Plane? No, It's a Hoverbike

Reuters - Business Video Online (Aug. 22, 2014) — UK-based Malloy Aeronautics is preparing to test a manned quadcopter capable of out-manouvering a helicopter and presenting a new paradigm for aerial vehicles. A 1/3-sized scale model is already gaining popularity with drone enthusiasts around the world, with the full-sized manned model expected to take flight in the near future. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Coal Gas Boom in China Holds Climate Risks

Coal Gas Boom in China Holds Climate Risks

AP (Aug. 22, 2014) — China's energy revolution could do more harm than good for the environment, despite the country's commitment to reducing pollution and curbing its carbon emissions. (Aug. 22) Video provided by AP
Powered by NewsLook.com
Former TSA X-Ray Scanners Easily Tricked To Miss Weapons

Former TSA X-Ray Scanners Easily Tricked To Miss Weapons

Newsy (Aug. 21, 2014) — Researchers found the scanners could be duped simply by placing a weapon off to the side of the body or encasing it under a plastic shield. Video provided by Newsy
Powered by NewsLook.com
Flower Power! Dandelions Make Car Tires?

Flower Power! Dandelions Make Car Tires?

Reuters - Business Video Online (Aug. 20, 2014) — Forget rolling on rubber, could car drivers soon be traveling on tires made from dandelions? Teams of scientists are racing to breed a type of the yellow flower whose taproot has a milky fluid with tire-grade rubber particles in it. As Joanna Partridge reports, global tire makers are investing millions in research into a new tire source. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins